Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7531 to 7545 of 8314 results

  1. Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

    This advice has been replaced by NICE HealthTech guidance 521.

    Medtech innovation briefing
    Published
    27 October 2017

  2. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE HealthTech guidance 530.

    Medtech innovation briefing
    Published
    18 January 2018

  3. LiverMultiScan for liver disease (MIB181)

    This advice has been updated and replaced by NICE healthtech guidance 655.

    Medtech innovation briefing
    Published
    26 April 2019

  4. TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure (MIB298)

    This advice has been updated and replaced by NICE healthtech guidance 730.

    Medtech innovation briefing
    Published
    31 May 2022

  5. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This advice has been updated and replaced by NICE healthtech guidance 729.

    Medtech innovation briefing
    Published
    7 March 2023

  6. The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)

    This advice has been updated and replaced by NICE guidance HTG441 

    Medtech innovation briefing
    Published
    13 October 2015

  7. Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)

    This advice has been updated and replaced by NICE healthtech guidance 657.

    Medtech innovation briefing
    Published
    4 May 2021

  8. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This advice has been updated and replaced by NICE healthtech guidance 708.

    Medtech innovation briefing
    Published
    1 June 2021

  9. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  10. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  11. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  12. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued Reference number: GID-TA10327

    Technology appraisal guidance
    Discontinued

  13. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued Reference number: GID-TA10309

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued